Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Wolfe

Showing results (31-40 of 295) with videos related to

Pageof 30
Sort By:
Biotechniques|October 1, 1995
Use of insoluble fusion proteins to purify antibodiesJ Luo, B B Wolfe
Memory & Cognition|August 18, 2000
Memory and judgment: availability versus explanation-based accountsM B Wolfe, N Pennington
Health Physics|August 1, 1988
Health and low-level radiation: turning good news into bad newsB Wolfe, L R Wallis
Journal of the American Chemical Society|May 30, 1973
The problem of pH in micellar catalyzed reactionsC A Bunton, B Wolfe
Death Studies|August 16, 2001
Ramblings from the trenches: a clinical perspective on thanatological researchB Wolfe, J R Jordan
Cell|April 1, 1984
Bacterial leader peptidase, a membrane protein without a leader peptide, uses the same export pathway as pre-secretory proteinsP B Wolfe, W Wickner
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1986
Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvertD W Gil, B B Wolfe
Annals of the New York Academy of Sciences|May 10, 1995
Development of selective antisera for muscarinic cholinergic receptor subtypesB B Wolfe, R P Yasuda
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1995
3-Isobutyl-1-methylxanthine increases alpha-1-adrenergic receptor sensitivity and density in DDT1-MF2 smooth muscle cellsJ B Schachter, B B Wolfe
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1985
Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclaseD W Gil, B B Wolfe
Pageof 30

Showing results (31-40 of 295) with videos related to

Sort By:
Pageof 30
Biotechniques|October 1, 1995
Use of insoluble fusion proteins to purify antibodiesJ Luo, B B Wolfe
Memory & Cognition|August 18, 2000
Memory and judgment: availability versus explanation-based accountsM B Wolfe, N Pennington
Health Physics|August 1, 1988
Health and low-level radiation: turning good news into bad newsB Wolfe, L R Wallis
Journal of the American Chemical Society|May 30, 1973
The problem of pH in micellar catalyzed reactionsC A Bunton, B Wolfe
Death Studies|August 16, 2001
Ramblings from the trenches: a clinical perspective on thanatological researchB Wolfe, J R Jordan
Cell|April 1, 1984
Bacterial leader peptidase, a membrane protein without a leader peptide, uses the same export pathway as pre-secretory proteinsP B Wolfe, W Wickner
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1986
Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvertD W Gil, B B Wolfe
Annals of the New York Academy of Sciences|May 10, 1995
Development of selective antisera for muscarinic cholinergic receptor subtypesB B Wolfe, R P Yasuda
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1995
3-Isobutyl-1-methylxanthine increases alpha-1-adrenergic receptor sensitivity and density in DDT1-MF2 smooth muscle cellsJ B Schachter, B B Wolfe
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1985
Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclaseD W Gil, B B Wolfe
Pageof 30